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Abstract
We have screened human adenoviruses (Ads) for oncolytic activity against a variety of mouse and hamster cell
lines and have found a number that are susceptible to a variety of Ad serotypes. A20 lymphoma is derived from
BALB/c mice and is susceptible to infection and killing by a variety of human Ads. A20 is also a suitable cancer
vaccine model, because these cells express a unique immunoglobulin variable region that can be targeted by
vaccination. To compare Ads as cancer vaccines versus Ads as oncolytics, A20 tumors were initiated in im-
munocompetent BALB/c mice. Mice immunized with first-generation Ad5 expressing the A20 immunoglobulin
ScFv immunogen (Ad-A20) were protected against A20 lymphomas only when the vaccine was delivered before
tumor. In contrast, vaccination after tumor initiation failed to increase survival or delay tumor growth. When Ad
serotypes from species B, C, D, and E were tested as oncolytics in vitro, A20 cells were most efficiently killed by
species D Ads, with intermediate activity by species B Ads. When tested in vivo in immunocompetent BALB/c
mice bearing A20 tumors, single intratumoral injection of species D Ad26 and Ad48 were effective at controlling
tumor growth. These data demonstrate that in this immunocompetent mouse cancer model, the oncolytic
activity of adenoviruses is more potent than their use as a cancer vaccine. These data in immunocompetent mice
lend further support to species D Ads as promising oncolytic viruses against B cell cancers.
Introduction
Bcell lymphomas are potentially unique cancer vaccinetargets, because they can express unique rearranged im-
munoglobulin idiotypes. Previous studies have shown that
protective immunity can be generated against this unique
feature (Stevenson et al., 1995; Hakim et al., 1996; Syrengelas
et al., 1996; King et al., 1998). Immunization with DNA
vaccines expressing the single-chain FV (scFv) and the scFv
fused to cholera toxin have been shown to induce protec-
tive immunity against lymphoma and myeloma (King et al.,
1998; Syrengelas and Levy, 1999). Hawkins and colleagues
fused the scFv of the lymphoma cell line A20 to the human
IgG1 Fc fragment (A20scFv-hFc) (Armstrong et al., 2002).
Recombinant adenovirus expressing A20scFv-hFc was used
to immunize BALB/c mice. On challenge > 40% of mice
were protected against a challenge with a lethal dose of
A20 cells (Armstrong et al., 2002). DNA immunizations of
scFv fused to the fragment C from tetanus toxin protected
mice against A31 lymphoma and 5T33 myeloma cell lethal
challenges (King et al., 1998). Technological advances in the
sequencing of immunoglobulin scFv of tumors are prom-
ising and it has been suggested that individualized tumor
vaccinations could be generated against lymphomas and
myelomas (Doenecke et al., 1997).
Although cancer vaccines are attractive, the ability to
stimulate protective immunity after tumor formation is the
ultimate goal. A comparable system would be that of the
rabies vaccine. In this system the infection has already
occurred and postexposure prophylaxis (PEP) consists of
anti-rabies immunoglobulin (RIG) and three to five immu-
nizations with killed inactivated rabies virus (Rupprecht and
Gibbons, 2004). In this system, the rabies virus is slow-
growing and requires several weeks to months to travel
through the CNS and reach the brain, ultimately resulting in
death (Faber et al., 2009). However, before the rabies virus
travels through the CNS and reaches the brain the RIG slows
it down and the immune responses stimulated by the vaccine
catch up, control, and eradicate the infection (Rupprecht and
Gibbons, 2004). Cancer vaccines that use the unique immu-
noglobulin of lymphomas and myelomas need to be able to
achieve this type of PEP.
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Although chemotherapeutics and surgery are the standard
for cancer treatment, they are invasive and toxic to healthy
tissue. Researchers have been searching for alternatives to
these standards and have extensively explored the use of
viruses to control, reduce, or eliminate tumors. Modifications
in the adenovirus serotype 5 (Ad5) genome have increased
the efficiency with which tumor cells are targeted and de-
stroyed (Fueyo et al., 2000; Nettelbeck et al., 2002; Reid et al.,
2002). Measles virus was also modified to target tumor
specific cells by displaying anti-CD38 and epidermal-like
growth factor receptor (EGFR) scFv (Nakamura et al., 2005).
Others have exploited the natural ability of vesicular sto-
matitis virus (VSV) to replicate in cancer cells in the presence
of interferon that would protect normal primary cells (Stojdl
et al., 2000). Vaccinia virus, herpesvirus, reovirus, and po-
liovirus have also been modified and studied for their ability
to effectively replicate in and destroy tumor cells (Gromeier
et al., 2000; Todo et al., 2001; Hirasawa et al., 2002; Parato
et al., 2005; Kirn et al., 2007). In this study we explored the use
of an adenovirus-vectored scFv vaccine against an A20
lymphoma tumor cell line in an immunocompetent BALB/c
mouse model. Here we show that the prevention of lym-
phoma tumors can be achieved only if the mice are immu-
nized before tumor formation, and that PEP is not achievable
once tumors are established. However, virotherapy using
wild-type adenoviruses (wtAds) was achievable in estab-
lished tumors and offers a new platform for vaccine vector
development and cancer therapy.
Materials and Methods
Viruses and cell lines
A20 is a B cell lymphoma cell line derived from an old
BALB/cAnN mouse (Kim et al., 1979). A20 cells were pur-
chased from the American Type Culture Collection (TIB-208;
ATCC, Manassas, VA) and were cultured in complete RPMI
containing 10% fetal bovine serum. The wild-type adeno-
viruses Ad4, Ad5, Ad6, Ad17, Ad24, Ad26, Ad28, Ad30,
Ad35, Ad45, and Ad48 were purchased from the ATCC and
grown in HEK-293 cells (CRL-1573; ATCC). The A20 scFv-
expressing virus (Ad-A20) was made with an AdEasy ex-
pression system (Agilent Technologies, Santa Clara, CA). The
A20 scFv was purchased from GenScript (Piscataway, NJ) and
cloned into the AdEasy expression system as previously de-
scribed (Armstrong et al., 2002). Ad-A20 virus was rescued
and amplified in HEK-293 cells. The viruses were purified
using two consecutive CsCl centrifugations and quantitated
by determining the optical density at 260 nm (OD260).
Mice
Female BALB/c mice (6–8 weeks old) were purchased
from Charles River Laboratories (Wilmington, MA) and
housed in the Mayo Clinic (Rochester, MN) Animal Facility
under the Association for Assessment and Accreditation of
Laboratory Animal Care (AALAC) guidelines with animal
use protocols approved by the corresponding Mayo Clinic
Institutional Animal Care and Use Committee. All animal
experiments were carried out according to the provisions of
the Animal Welfare Act, PHS Animal Welfare Policy, the
principles of the NIH Guide for the Care and Use of Laboratory
Animals, and the policies and procedures of the Mayo Clinic.
Anti-A20 immunization
Mice were anesthetized intraperitoneally with ketamine
(140 mg/kg)–xylazine (5.55 mg/kg) and were immunized
intramuscularly with 1010 viral particles (VP) of Ad-A20 in a
volume of 50 ll (n = 10). Twenty-five microliters was injected
into each mouse quadriceps. Three weeks postimmunization
the mice were boosted with 1010 VP of Ad-A20. Control mice
were injected with Dulbecco’s phosphate-buffered saline
(DPBS) or a nonspecific green fluorescent protein (GFP)/
luciferase-expressing Ad (Ad-GL). Two weeks postimmuniza-
tion 106 A20 cells were injected subcutaneously to induce
tumors. Tumors were measured weekly and mice were hu-
manely killed when tumors reached a volume of 2000 ll.
Analysis of in vitro infection and killing
of A20 cells by wild-type Ads
A20 cells were infected with 10,000 VP per cell for 1 hr at
4C. Cells were then washed three times with Hanks’ buff-
ered saline solution (Invitrogen, Carlsbad, CA) and placed in
a 37C incubator for the indicated length of time. Loss of
membrane integrity was assessed by trypan blue uptake as
described by Barry and colleagues (1990).
Tumor control by wild-type Ads
A20 cells (106) were injected subcutaneously into the hind
flank of 6- to 8-week-old BALB/c mice. When the tumors
reached an average size of 200 ll they were injected in-
tratumorally with 3 · 1010 VP of wild-type virus in a 100-ll
total volume of DPBS. Control groups were injected with
buffer alone. Tumors were observed every other day and
measured weekly. Volume was calculated as ½ length ·
width · width. Animals were killed when tumor volume
exceeded 2000 ll, were found with ulcerated tumors, or had
weight loss greater than 20%.
Results
Prophylactic immunization by Ad against A20 tumors
Groups of female BALB/c mice were immunized intra-
muscularly with 1010 VP of replication-defective Ad-A20
expressing the A20 ScFv immunogen (n = 10). Three weeks
later, the mice were boosted with 1010 VP of Ad-A20. Control
mice were injected with DPBS or a nonspecific GFP/luciferase-
expressing Ad (Ad-GL). Two weeks after immunization A20
tumors were initiated by subcutaneous injection of 106 A20
cells into the flanks.
Mice that received a prime–boost immunization of Ad-
A20 virus were capable of inhibiting A20 tumor growth
(Fig. 1A). In fact, all Ad-A20-immunized mice suppressed
A20 tumor growth for 4 weeks after injection as compared
with control mice. However, three of the immunized mice
lost control of tumor growth and A20 tumors reestablished
at a growth rate similar to the controls (Fig. 1A). The sur-
vival curves for the Ad-A20-immunized mice were signifi-
cantly different as compared with the Ad-GL and DPBS
mice ( p = 0.0005 and p £ 0.0001, respectively). Seven of the
immunized mice survived the A20 tumor challenge
whereas none of the control DPBS-immunized mice and
only one of the control Ad-GL immunized mice survived
(Fig. 1B).
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Established A20 tumors are not controlled
by Ad-A20 immunization
Groups of eight mice were injected with A20 cells. When
the tumors reached an average size of 200 ll, the mice were
immunized intramuscularly with 3 · 1010 VP of Ad-A20 or
control DPBS and tumor growth and survival were moni-
tored. Control of established tumors by immunization with
Ad-A20 was not achieved (Fig. 2). Although the tumor
growth in Ad-A20-immunized mice appeared to be delayed
(Fig. 2A), the ultimate survival rates among the immunized
and control mice were equivalent (Fig. 2B). There were no
significant differences in tumor size or survival between
immunized and control animals.
Analysis of in vitro infection and killing
of A20 cells by human adenoviruses
We tested a panel of adenoviruses from species B, C, D, E,
and F against human solid and B cell cancers (Shashkova
et al., 2009; Senac et al., 2010; Chen et al., 2011a,b). To test this
for mouse B cell-derived A20 lymphoma cells, A20 cells were
infected with 10,000 VP per cell for 1 hr at 4C. The cells were
then washed three times with Hanks’ buffered saline solu-
tion (Invitrogen) and placed in a 37C incubator for the in-
dicated length of time. Cell killing, as demonstrated by loss
of membrane integrity, was assessed by trypan blue uptake
as in Barry and colleagues (1990) (Fig. 3). Consistent with
data in human cells (Senac et al., 2010; Chen et al., 2011a,b),
species D Ads had highest activity against these B cell can-
cers, with lower killing by species B Ad35, species C Ad5 and
Ad6, and species E Ad4. Of these viruses, species D Ad26
and Ad48 appeared most robust.
Control of tumor growth by wild-type Ads
Given that the wild-type Ads appeared to have oncolytic
activity in vitro against A20 cells, the oncolytic activities of a
FIG. 1. Prophylactic immunization against A20 tumor
growth. Mice that received a prime–boost immunization with
1010 VP of Ad-A20 virus were capable of inhibiting A20 tumor
growth (A). The survival curves for the Ad-A20-immunized
mice were significantly different as compared with the Ad-GL
and DPBS mice ( p = 0.0005 and p £ 0.0001, respectively). Seven
of the immunized mice survived the A20 tumor challenge
whereas none of the control DPBS immunized mice, and only
one of the control Ad-GL-immunized mice, survived (B).
FIG. 2. Therapeutic control of established tumors. Groups of
eight mice were injected with 106 A20 cells. When the tumors
reached an average size of 200 ll, the mice were immunized
intramuscularly with 3 · 1010 VP of Ad-A20 or control DPBS.
Control of established tumors by immunization with Ad-A20
was not achieved. Although the tumor growth in Ad-A20-
immunized mice appeared to be delayed (A) the ultimate
survival rates of the immunized and control mice were
equivalent (B). There were no significant differences in tumor
sizes or survival between immunized and control.
FIG. 3. Analysis of in vitro infection and killing of A20 cells by
wild-type Ads. A20 cells were infected with 10,000 VP per cell
for 1 hr at 4C. Cells were then washed three times with Hanks’
buffered saline solution (Invitrogen, Carlsbad, CA) and placed
in a 37C incubator for the indicated length of time. Loss of
membrane integrity was assessed by trypan blue uptake. Color
images available online at www.liebertonline.com/hum
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select set of viruses were tested in vivo in immunocompetent
BALB/c mice (Fig. 4). Groups of seven or eight mice were
injected subcutaneously with 106 A20 cells. When the tumors
averaged 200 ll, they were injected intratumorally with
3 · 1010 VP of wild-type Ad5, Ad6, Ad26, and Ad48 viruses
and tumor size and survival were monitored. Under these
conditions, Ad48 induced the greatest delay in tumor growth
(Fig. 4A). When survival was monitored, 60% of animals still
survived through 9 weeks after single treatment with either
Ad26 or Ad48 (Fig. 4B); however, only Ad48 mouse survival
was statistically different from that of buffer-treated animals
( p = 0.0299). In contrast, Ad6-treated mouse survival was no
better than that of buffer-treated animals and Ad5-treated
mouse survival was only slightly better. The individual tumor
volumes for the wild-type Ad-treated groups are shown in
Supplementary Fig. S1 (supplementary data are available
online at www.liebertonline.com/hum).
Discussion
The vast majority of studies of Ad as a vaccine or of Ad as
an oncolytic have used species C Ad5 as a vector. Although
Ad5 is robust, it is arguably one of the least practical viruses
for use in humans, because 27–100% of humans are immune
to the virus. Given these issues, we and others have explored
other low-seroprevalence Ads for use as oncolytic and vac-
cine vectors. In the course of our studies (Senac et al., 2010;
Chen et al., 2011a,b), we have found that the relatively un-
studied species D adenoviruses have surprisingly high ac-
tivity as oncolytics against B cell cancers.
At the same time, studies of Ad5 and other Ad serotypes
have been hampered by the necessity to use the viruses in
immunodeficient mouse xenograft models, because these
viruses do not propagate well in most nonhuman cells.
Given this, we have tested human Ads from species B, C, D,
E, and F for their ability to infect nonhuman cancer cell lines
to allow testing in immunocompetent animal models. In this
work, we have found that the popular HaK kidney cancer
cell line from Syrian hamsters is indeed permissive as re-
ported for Ad5 infection, but that the only other virus that
would kill these cells was another species C virus, Ad6 (Chen
et al., 2011a). In contrast, all other tested Ad serotypes failed
to kill HaK cells, rendering them unsuitable for testing non-
Ad6 or Ad6 viruses. Subsequent testing in a range of mouse
cell lines including A20 identified several that support in-
fection of a variety of Ad serotypes. Given the permissivity
of A20 to various Ad serotypes and prior experience in using
it as a cancer vaccine model (Armstrong et al., 2002), in this
study we compared Ad vaccine and Ad oncolytic activities
in this unique immunocompetent model.
In this work, we found that adenovirus expressing the A20
tumor cell line scFv was capable of inducing protective im-
mune responses against a lethal A20 tumor challenge. The
protective immune response was most likely enhanced by the
anamnestic responses induced by the subsequent injection of
mice with A20 tumor cells. We found that we were able to
protect 70% of mice from tumor formation and death as
compared with previous reports of <20% protection (Arm-
strong et al., 2002). Although delayed, three of the immunized
mice did establish tumors. As there are no known correlates of
protection against these tumors, the mechanism of protection
and failure to control tumor progression is unknown. How-
ever, we speculate that the delayed tumor formation may
indicate the establishment of tolerance in mice that were un-
able to completely clear the tumor cells. Although this was
promising, this cancer vaccine approach was effective only if
the animals were immunized before exposure to the tumor, a
situation that generally does not exist in human cancer pa-
tients. In contrast to prophylactic protection, vaccination after
tumors had already formed failed to inhibit tumor progres-
sion. This does not mean that such a cancer vaccine could
never have utility. Rather, in this setting it was less effective
than other interventions. A20 tumors are rapidly established
and progress with a doubling approximately every week. In
this model, tumors form and become lethal ( >2 cm3) within 4
to 7 weeks. The A20 lymphoma model represents an aggres-
sive form of disease. A less aggressive, slower model may
result in a different outcome and may be more representative
of slower-progressing lymphomas. Alternatively, combining
vaccination with treatments such as chemotherapy, immu-
notherapy, or alternative approaches such as statin inhibition
of tumor progression may allow for the induction of protec-
tive immune responses and result in greater levels of treat-
ment efficacy (Czuczman et al., 1999; Demierre et al., 2005). It
should also be noted that this tumor vaccine model is in the
FIG. 4. Control of tumor growth by wild-type Ads. Groups
of seven or eight mice were injected with A20 cells. When the
tumors averaged 200 ll, they were injected intratumorally
with 3 · 1010 VP of the wild-type viruses that induced
greatest levels of killing in vivo. Ad48 induced the greatest
delay in tumor growth (A). Ad26 and Ad48 had the greatest
levels of survival against A20 tumor growth (B). Both Ad26
and Ad48 were capable of clearing established tumors in
mice and protected four of seven mice from death. However,
only Ad48 was statistically significant as compared with
DPBS ( p = 0.0299).
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context of an immunocompetent mouse; it cannot be directly
translated to humans. It is possible that protective immune
responses against established tumors could be generated in a
different genetic background.
Because vaccination against established A20 tumors was
unsuccessful we tested whether replication-competent ade-
noviruses might instead have utility as oncolytics rather than
vaccines. When 11 wild-type human Ads were tested in vitro,
A20 cells were killed most efficiently by species D Ads. This
is consistent with a number of studies against human B cell
cancers using cell lines and primary patient samples. Pre-
vious studies on primary multiple myeloma patient samples
showed that species D Ad26 and Ad48 killed CD138 + my-
eloma cells better than species C Ad5 and Ad6, which were
better than species B Ad11 and Ad35 (Senac et al., 2010).
Subsequent studies in lymphoma and myeloma cell lines and
patient samples have demonstrated that many species D
viruses have higher oncolytic activity than Ads from other
species in vitro and in immunodeficient mouse xenografts of
lymphoma (Chen et al., 2011b). When Ad26 and Ad48 were
compared with Ad5 and Ad6 in this immunocompetent
mouse model of lymphoma, the species D viruses were again
most effective in controlling these B cell cancers. Importantly,
Ad26 and Ad48 were effective after single treatment and in
the context of an intact immune system.
In summary, these data suggest that adenovirus may be
more effective when applied as an oncolytic rather than a
cancer vaccine, at least in this model. Previous data against
primary patient samples suggest these viruses can kill the
cancer cells that are present in patients. The present data
suggest they can act as effective oncolytics in the face of a
fully functional immune system. These data suggest that
species D adenoviruses may have utility as oncolytic agents
against B cell cancers.
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